What was the primary driver of Medtronic's significant revenue growth in this period?

The primary driver of Medtronic's substantial revenue growth was the acquisition of Covidien plc, which closed on January 26, 2015. This acquisition significantly expanded the company's product portfolio and market reach, contributing $2.291 billion and $7.103 billion in net sales for the three and nine months ended January 29, 2016, respectively.

Why did Medtronic's net income decrease despite the significant increase in net sales?

While net sales increased substantially due to the Covidien acquisition, net income decreased by 9% for the nine-month period. This was primarily due to increased costs associated with the acquisition, including higher cost of products sold (impacted by an inventory fair value adjustment), increased amortization of intangible assets, restructuring charges related to cost synergy initiatives, and acquisition-related integration costs. These factors, among others, outweighed the revenue gains.

How is Medtronic managing the costs associated with the Covidien integration and its overall cost structure?

Medtronic is actively pursuing cost synergy initiatives stemming from the Covidien acquisition, with an anticipated $850 million in savings by fiscal year 2018. These initiatives involve optimizing administrative offices, manufacturing, and supply chain infrastructure. The company also incurred restructuring charges related to these efforts, indicating a proactive approach to managing costs and integrating the acquired business.

What is Medtronic's approach to managing foreign currency exchange rate fluctuations, and what was their impact in this period?

Medtronic uses operational and economic hedges, along with currency exchange rate derivative instruments, to mitigate the impact of currency fluctuations. For the three and nine months ended January 29, 2016, foreign currency translation had an unfavorable impact on net sales of $344 million and $1.323 billion, respectively. The primary currencies affecting these impacts were the U.S. dollar against the Euro and Japanese Yen.

MDT 10-Q Quarterly Report Q3 FY2016 — Revenue, Net Income, EPS

Summary

Medtronic plc's (MDT) Form 10-Q filing for the period ending January 28, 2016, reveals significant growth driven by the acquisition of Covidien, which closed in January 2015. Total net sales for the nine months ended January 29, 2016, increased by 64% to $21.266 billion. While revenue saw a substantial boost, the company also reported a net income decrease of 9% for the nine-month period compared to the prior year, attributed to increased costs associated with the acquisition, including higher cost of products sold and amortization of intangible assets. The company is actively managing its cost structure through restructuring initiatives aimed at achieving cost synergies from the Covidien integration. Despite the increased expenses and a notable decline in net income for the nine months, Medtronic demonstrated strong operational cash flow generation of $3.892 billion. The company continues to invest in research and development to drive future growth and is focused on returning value to shareholders through share repurchases and dividends. Management highlighted ongoing integration efforts and strategic product launches across its key segments, including Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes, indicating a strategic focus on innovation and market expansion.

Financial Highlights

51 data points

Beta

Revenue

$6.93B

0.7% Gross Margin

Net Income

$1.09B

0.2% Net Margin

EPS (Diluted)

$0.77

Total Assets

$102.71B

Cash & Equivalents

$2.72B

Free Cash Flow

$1.55B

Financial Statements

Beta

Revenue	$6.93B
Cost of Revenue	$2.14B
Gross Profit	$4.79B
SG&A Expenses	$2.32B
Operating Income	$1.35B
Interest Expense	$275.00M
Net Income	$1.09B
EPS (Basic)	$0.78
EPS (Diluted)	$0.77
Shares Outstanding (Basic)	1.41B
Shares Outstanding (Diluted)	1.42B

Key Highlights

1Net sales for the nine months ended January 29, 2016, surged by 64% to $21.266 billion, largely due to the acquisition of Covidien, which closed on January 26, 2015.
2Net income for the nine months ended January 29, 2016, decreased by 9% to $2.435 billion, compared to $2.676 billion in the prior year, reflecting increased costs and acquisition-related expenses.
3Operating profit increased by 11.6% to $3.786 billion for the nine months ended January 29, 2016.
4Operating cash flow for the nine months ended January 29, 2016, was $3.892 billion, a significant increase from $2.990 billion in the prior year, indicating strong cash generation capabilities.
5The company incurred substantial restructuring charges and acquisition-related costs, totaling $208 million and $183 million, respectively, for the nine months ended January 29, 2016, as part of the Covidien integration and cost synergy initiatives.
6Amortization of intangible assets significantly increased to $1.448 billion for the nine months ended January 29, 2016, up from $265 million in the prior year, primarily due to the Covidien acquisition.
7Medtronic continued to return value to shareholders through share repurchases ($2.170 billion for the nine months) and dividends ($1.608 billion for the nine months).

Medtronic plc Quarterly Report for Q3 Ended Jan 29, 2016

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions